FDA grants Orphan Drug status for Shift’s lead compound for SMA – May 2020

Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A
treatment – February 2020

The Gwendolyn Strong Foundation and National Institute of Health fund Shift Pharmaceuticals – December 2019

Congressional Directed Medical Research Program (CDMRP) awards grant to Shift for the company’s lead compound for SMA – November 2018